Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Atb Therapeutics currently manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This prosecution activity involves a distinct examiner and is contained within a distinct art unit. This reflects a singular and focused interaction with the patent office for the company's current pending matters.
FAUST, AMBER KATHLEEN is the busiest examiner for the portfolio, responsible for 1 pending office action. This action represents the entirety of the company's pending office actions. The concentration of the workload under a distinct examiner in a distinct art unit highlights a specific focus within the Biotechnology & Pharmaceuticals sector.
For practitioners, the presence of a single pending office action indicates a very targeted prosecution front. The use of a distinct art unit suggests that the technology under review is specialized and does not currently span multiple technical classifications. This allows for a precise evaluation of the company's current patenting objectives and examiner engagement. In the Biotechnology & Pharmaceuticals field, this level of focus often points to a targeted application for a specific therapeutic or biological discovery.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FAUST, AMBER KATHLEEN | 1 | 60.6% | +53.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18041770 | RECOMBINANT IMMUNOTOXIN COMPRISING A RIBOTOXIN OR RNASE | FAUST, AMBER KATHLEEN | 21d |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18041770 | RECOMBINANT IMMUNOTOXIN COMPRISING A RIBOTOXIN OR RNASE | FAUST, AMBER KATHLEEN | 1643 | §103 | Final Rejection | 21d | Pending | Feb 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial